Staff Reports
The big news this week is a federal push to change how we treat mental illness. HHS Secretary Robert F. Kennedy Jr. introduced a MAHA Action Plan meant to curb “psychiatric overprescribing” and to promote deprescribing—especially for kids. It was rolled out at a Make America Healthy Again summit and backed by a Dear Colleague letter from SAMHSA and new CMS billing guidance. In plain English: the government wants doctors to talk more about therapy, exercise, sleep and taper plans before or alongside handing out pills.
What the MAHA Action Plan actually does
The plan tells federal agencies to prioritize informed consent and shared decision‑making when prescribing antidepressants and other psychiatric meds. SAMHSA’s letter urges clinicians to include nonpharmacological treatments in care plans and to consider supervised tapering when appropriate. CMS clarified that doctors can bill for deprescribing work—taper plans, monitoring and coordination—under certain Medicare codes. HHS says meds remain an option, but the focus will shift toward prevention, transparency, and holistic care. There are promises of webinars, a technical expert panel, and a SAMHSA report on prescribing trends to follow.
Good idea — in theory; watch out in practice
Let’s not pretend this is either pure virtue or pure villainy. Yes, antidepressant use has risen, especially in teens and young adults, and too many patients get a pill instead of therapy, family support, or simply sleep and exercise. Incentivizing counseling and careful tapering is sensible. But execution matters. Professional groups warn that abrupt or noncollaborative deprescribing can be dangerous. Secretary Kennedy’s past, loud claims about SSRIs make some clinicians nervous. Deprescribing must be clinician‑led, gradual, and tailored—not a bureaucratic checkbox or an excuse for insurers to deny care.
Politics, money, and medicine are a risky triangle
Here’s the part nobody in the press wants to say loudly: big pharma has a stake in keeping prescriptions flowing, and insurers have a stake in cutting costs. That can make “deprescribing” sound like common sense or like rationing, depending on who’s pulling the strings. The MAHA plan could nudge medicine toward commonsense measures like more therapy access and exercise programs. Or it could be twisted into a tool that limits access to medications for people who genuinely need them. The federal guidance must include safeguards: clear clinical rules, funding for nonmedication treatments, and protections for vulnerable children and adults.
Bottom line — sensible goal, messy path
The MAHA Action Plan is a notable policy shift. Encouraging informed consent, nonpharmacological care, and safe tapering is a step in the right direction if done carefully. But don’t let slogans replace science. Watch for the SAMHSA prescribing report, the technical panel recommendations, and any formal clinical guidance that follows. If Washington wants to curb overmedicating, it should pair good policy with real resources—therapy access, trained clinicians, and clear, safe taper protocols—not mere rhetoric or cuts dressed up as “reform.”
